Charles River to Acquire WIL Research Charles River Laboratories International, Inc.
|
|
- Asher McDowell
- 6 years ago
- Views:
Transcription
1 Charles River to Acquire WIL Research 2016 Charles River Laboratories International, Inc.
2 Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Forward-looking statements may be identified by the use of words such as anticipate, believe, expect, will, may, estimate, plan, outlook, and project and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements include statements in this presentation regarding the acquisition of WIL Research, expectations regarding the timing of the closing of the acquisition, and Charles River s expectations with respect to the impact of WIL Research on the Company, its service offerings, client perception, revenue, revenue growth rates, earnings, financing, stock repurchase activity, share count, credit facility, interest rates, tax rates, and operating margin; WIL Research s final 2015 reported financial results; Charles River s projected future performance including revenue and earnings per share; Charles River s expected operational synergies; as well as Charles River s future growth in the area of safety assessment and contract development and manufacturing. Forward-looking statements are based on Charles River s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to, the ability to successfully complete the acquisition of WIL Research. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 17, 2015, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law. Regulation G This presentation contains non-gaap financial measures, such as non-gaap earnings per diluted share, which exclude the amortization of intangible assets, certain third-party integration costs, certain costs associated with efficiency initiatives, and other charges related to our acquisitions and expenses associated with evaluating acquisitions. We exclude these items from the non-gaap financial measures because they are outside our normal operations. There are limitations in using non-gaap financial measures, as they are not prepared in accordance with generally accepted accounting principles, and may be different than non-gaap financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-gaap financial measures in this presentation helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions (and in certain cases, the evaluation of such acquisitions, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities, such as business acquisitions, happen irregularly and the underlying costs associated with such activities do not recur on a consistent basis. Non-GAAP results also allow investors to compare the Company s operations against the financial results of other companies in the industry who similarly provide non-gaap results. The non-gaap financial measures included in this presentation are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to periodically assess the potential value of reporting non-gaap results consistent with applicable rules and regulations. Quiet Period Disclaimer The Company is presently in quiet period pending its fourth-quarter and full-year 2015 earnings and 2016 guidance release on February 11, As a result, the Company will not comment on financial performance for the fourth quarter of 2015 or guidance for
3 Transaction Overview On January 7, 2016, Charles River announced that we have entered into a definitive agreement to acquire WIL Research for ~$585M in cash subject to certain adjustments A premier provider of safety assessment services and contract development and manufacturing services (CDMO) for biopharma and agricultural/industrial chemical clients worldwide Seizing a unique opportunity to acquire a premier provider with complementary capabilities Enhances CRL s position as a leading early-stage CRO Drives profitable revenue growth and immediate EPS accretion 3
4 Transaction Overview, cont. Believe WIL Research is an exceptional strategic fit for CRL: Excellent quality and scientific expertise Attractive geographic footprint, particularly in continental Europe Complementary capabilities in different regions Complementary client base and access to new clients Very similar culture to CRL, focusing on supporting employees and delivering exceptional science and service to clients A highly respected provider of safety assessment and CDMO services with a reputation built over 40 years 4
5 Financial Details Purchase price of ~$585M equates to non-gaap EBITDA multiples of: 12.9x in FY 2015E ~11x in FY 2016E including operational synergies WIL s revenue estimated at ~$215M in 2015 with mid-teens non-gaap operating margin Represents YOY revenue growth of ~9% (constant currency) in 2015 Expected to generate operational synergies of ~$17M-$20M within 2 years of closing Immediately accretive to non-gaap EPS and expected to exceed ROIC hurdle within our required timeframe of 3-4 years At least $0.20 accretive to 2016 assuming an early 2Q16 close $0.45-$0.50 accretive in 2017 Creates value for shareholders 5
6 Financial Details, cont. Acquisition and associated fees expected to be financed through expansion of credit facility Intend to increase borrowing capacity by $350M to $1.65B ($650M term loan & $1B revolver) Chose this approach because of our demonstrated ability to generate strong free cash flow Pro forma leverage ratio expected to be ~3.5x after close Expect to drive pro forma leverage below 3x within 18 months of closing Intend to deploy free cash flow to debt repayment over next 18 months Will limit stock repurchase activity resulting in modest increase to diluted share count Based on pro forma leverage, interest rate expected to increase to LIBOR+150 bps post-closing for drawn amounts (current: LIBOR bps) 6
7 Financial Details, cont. Due to geographic earnings mix, expect WIL s earnings to be taxed at a higher rate (~35%) than CRL s consolidated tax rate Expect to close in early 2Q16 Subject to regulatory approvals and customary closing conditions Expect to report WIL primarily in DSA segment 7
8 Strategic Rationale BUILDS GLOBAL SCALE Provides capacity to support current demand and future growth Strategically located facilities to address global client requirements Adds needed footprint in continental Europe Expands CRL s global footprint for existing specialty services DIVERSIFIES PORTFOLIO Extends ability to partner with biopharma clients through new CDMO services Adds new services in safety assessment and bioanalysis Niche high-end specialty services for complex applications EXPANDS CLIENT BASE Aligns with strategy to build small and midsize biotech client base, our fastestgrowing market segment Broadens existing business with industrial chemical and agro-chemical companies ENHANCES GROWTH PROFILE Addition of a leading CRO with an excellent reputation for high scientific expertise and focus on client service Positions CRL to drive profitable growth and realize meaningful earnings accretion 8
9 WIL Research s Scientific Capabilities General Toxicology WIL s Services Analytical Services 1 Comprehensive in vivo studies Single dose to carcinogenicity Studies include all standard research model species and methods of administration General Toxicology 42% Specialty Toxicology 30% Analytical chemistry, bioanalysis, formulation support, and physical chemistry Specializes in the analysis of small organic compounds, peptides, proteins, monoclonal antibodies, and other specimens Specialty Toxicology Includes specialized toxicology, discovery support studies, and safety pharmacology DART, juvenile, neuro, genetic, environmental/ecological, and inhalation toxicology Premier market reputation Other 2% Analytical Services 17% Formulation & Mfg. 9% Formulation & Manufacturing Pre-formulation, formulation design and development, manufacturing, and analytical/ stability testing for small molecules Specialized capabilities in highpotency compounds Enhances CRL s leading position in specialty services; Scientists with advanced degrees will total ~900 Note: Business mix as a percentage of 2015E revenue 1 Analytical services are primarily completed in support of WIL s general/specialty toxicology services. 9
10 Increased Access to Industrial & Agro-Chemical Clients Expertise in advanced toxicology services to support global industrial and agro-chemical clients in meeting regulatory requirements Environmental and eco-toxicology services Industrial and agro-chemical clients represent ~25% of WIL s 2015E revenue Expect mid-single digit market growth for the next 5 years to be driven by: Demand for chemicals to increase crop yields prompted by growing global population and limited land for food Recurring need for testing services due to regulatory requirement for re-registration every 10 years for agro-chemicals already on the market REACH initiative testing backlog and anticipated future testing expected to create significant demand through 2025 Combined capabilities will more than double the size of CRL s existing business 10
11 CDMO Platform Differentiates Portfolio and Provides Avenue for Growth Expertise in formulation design and development of oral drug dosages Adjacent capability that expands opportunities to partner with biopharma clients Supports small molecule formulation from discovery through clinical trials Specialized capabilities in high-potency compounds Key market drivers: Increased outsourcing trend expected to drive penetration higher from today s ~30% level Need to enhance efficiency and productivity of R&D spend Growth in drugs from small and mid-size biopharma companies lacking inhouse capabilities Increasing complexity of regulatory and compliance requirements Greater scrutiny by regulatory agencies Scalable platform in fragmented CDMO market that is expected to grow in the mid-to-high single digits for the next 5 years 11
12 WIL s Global Footprint Den Bosch / NL Ashland, OH Harrogate, UK 30% Biopharma / 70% Chemical 145,000 ft 2 80% Biopharma / 20% Chemical 325,000 ft 2 Client Services Lyon, FR Skokie, IL Fairfield, NJ Corporate Headquarters 95% Biopharma / 5% Chemical 195,000 ft 2 95% Biopharma / 5% Chemical 25,000 ft 2 Boothwyn, PA Hillsborough, NC Pathology 9,000 ft 2 100% Biopharma (CDMO) 43,000 ft 2 U.S. ~65% ROW ~35% Worldwide reach with ~1,300 employees and >700,000 ft 2 of capacity in US and Europe 12
13 Safety Assessment Opportunity Safety Assessment will be a significant opportunity for growth over the next 5 years At least 50% outsourced currently, expected to increase to 80% or more in the future Large biopharma continues to increase its utilization of outsourced services to leverage expertise and efficiencies that CROs offer Robust funding to virtual, small, and mid-size biotech, which require outsourced services ~$4B Outsourced Safety Assessment* Other CROs Charles River WIL Covance MPI Envigo Includes non-glp/glp SA services, bioanalysis and ag/ind chem services; market growth of ~7% CAGR* *Source: Wall Street research and management estimates. 13
14 Average In-Licensing Share of Major Biopharma Pipeline Rising* Large biopharma focusing less on who discovers the molecule and more on whether the molecule addresses a significant medical need Trend has funded many of the virtual, small, and mid-size biotech companies Have little or no infrastructure Rely almost exclusively on CROs like CRL Large biopharma s emphasis on early-stage R&D is driving: Industry capacity continuing to fill Improving industry pricing Share of Pipeline Supports CRL s continued growth through addition of services and capacity 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 25% 34% 37% 39% 41% 42% E * Parexel Biopharmaceutical R&D Statistical Sourcebook and Citeline, Inc. (Pharmaprojects/Pipeline). 14
15 Biotech Client Base WIL s primary client base is small and mid-size biotech One aspect of due diligence focused on assumptions of drivers of biotech outsourcing, sources for biotech funding, and impact on revenue if funding were to slow Large biopharma will continue to utilize biotech for discovery of new drugs Large biopharma has been leveraging biotech heavily since 2008 Has led to stronger and more productive pipelines Many of the drugs approved by the FDA in the last few years or currently in the pipeline are the products of large biopharma s collaboration with biotech We are very proud that CRL worked on 55% of the drugs approved by the FDA in 2014 We are respected for our scientific expertise and support we provide to clients Believe that acquisition of WIL will enhance our reputation 15
16 Biotech Funding Outlook Genomics/proteomics have come of age and are driving identification of new types of drugs, like immunotherapies, which are showing tremendous potential for curing disease Driving a steady increase in large pharma investment in biotech, as well as from capital markets and venture capital Biotech companies have a significant amount of cash on hand given the broad-based investment in the biotech sector Expect this cash to be invested over a minimum of 3 years, and likely longer Using VC funding as a proxy for the length of time it takes to get a drug to proof of concept suggests a period of 3-4 years Believe the horizon for large biopharma funding would likely be longer, and that contractual milestone payments would be made during that time 16
17 Combined Client Profile WIL acquisition aligns with CRL s strategy to build biotech client base and further diversifies client concentration WIL has low client concentration No single client represents more than 2.5% of WIL revenue Some CRL-WIL client overlap, as would be expected for similarly focused companies with a reputation for scientific expertise Two-thirds of WIL s YTD September 2015 revenue was generated from WIL clients that were either not CRL Safety Assessment (SA) clients or represented <$100K in CRL SA revenue WIL Client Profile Biotech 84% Global 14% Acad/Gov t 2% Biotech 50% Global 33% Acad/Gov t 17% Combined Pro Forma CRL Client Profile Note: Client profile is based on CRL s clients segments; percentages are based on YTD September 2015 revenue. 17
18 Disciplined M&A Strategy Delivering Compelling Financial Benefits Supported by CRL s Disciplined M&A Strategy Accretive on a non-gaap EPS basis in year one ROIC expected to meet or exceed cost of capital within 3-4 years Enhances organic growth opportunities Financial Impact Revenue Non-GAAP EPS accretion 2016E (1) ~$150M- $170M At least $ E ~$240M- $250M $0.45-$ Year Strategic Plan >10% revenue CAGR for combined CRL SA business Non-GAAP operating margin >20% (including WIL), due in part to benefits from efficiency initiatives and operational synergies Increased Shareholder Value (1) 2016 Partial-year contribution based on expected close in early 2Q16 18
19 Operational Synergies Implementation of operational synergies to begin in 2016 post-closing, with estimated benefits of ~$17M-$20M within 2 years of closing Operational synergies expected to be achieved through: Productivity and efficiency initiatives Optimize labor and capacity utilization Centralize certain services Procurement and insourcing synergies Expanded use of CRL s services and research models Leverage CRL s supplier relationships Corporate savings Reduction of duplicate corporate costs Leveraging CRL s productivity and efficiency expertise to achieve margin improvement goals 19
20 Operational Integration Plan Comprehensive integration planning already in process Dedicated integration resources In-house Finance, IT, and operational resources External consultants for short-term support SVP Birgit Girshick to manage the operational integration full time >25 years of operational experience Focus on utilizing best-in-class processes from both companies and applying CRL operating efficiency expertise Priority to achieve cost synergies Similar cultures and operational core competencies facilitate integration 20
21 Acquisition Summary 1 Expands and further differentiates CRL s position as a leading early-stage research and development CRO 2 Provides additional capabilities and infrastructure to support current client demand and future growth and critical footprint in continental Europe 3 Adds well-recognized platform tailored to fast-growing small and mid-size biopharma clients 4 Provides larger presence in agro-industrial chemical business and new capabilities in CDMO industry 5 Reinforces scientific leadership: Adds wealth of scientific talent with deep experience in specialty areas 6 Drives revenue growth and immediate accretion to non-gaap EPS; meets ROIC hurdles 21
22 2016 Charles River Laboratories International, Inc.
A full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationOverview of USI Acquisition. March 2, 2018
Overview of Acquisition March, 08 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements
More informationNon Deal Roadshow - Europe
Non Deal Roadshow - Europe 2015 May Analyst Meeting February/March 2016 The world leader in serving science The world leader in serving science Non-GAAP Measures This presentation contains certain financial
More informationCB&I Investor Presentation March 2017
A World of Solutions CB&I Investor Presentation March 2017 A Leading Provider of Technology and Infrastructure for the Energy Industry Safe Harbor Statement This presentation contains forward-looking statements
More informationWESTFALIA AUTOMOTIVE ACQUISITION AUGUST 25, 2016
WESTFALIA AUTOMOTIVE ACQUISITION AUGUST 25, 2016 1 SAFE HARBOR STATEMENT FORWARD-LOOKING STATEMENTS This presentation may contain "forward-looking statements" as defined in the Private Securities Litigation
More informationTSYS to Acquire Cayan
TSYS to Acquire Cayan Solidifying TSYS Leadership Position in Technology-Led SMB Merchant Services December 18, 2017 Forward Looking Statements This slide presentation and comments made by management contain
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.
More informationTriNet Group, Inc. Investor Presentation November 2017
TriNet Group, Inc. Investor Presentation November 2017 Disclaimer Cautionary Note Regarding Forward-Looking Statements and Other Financial Information This presentation contains statements that are not
More informationHewlett Packard Enterprise SEC Form 10 Filing
Hewlett Packard Enterprise SEC Form 10 Filing Investor Presentation July 1, 2015 Forward looking statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions
More information16th Annual ICR XChange Conference January 14, 2014
16th Annual ICR XChange Conference January 14, 2014 Bill DeLaney President, Chief Executive Officer Chris Kreidler Executive Vice President, Chief Financial Officer Forward-Looking Statements Statements
More informationWESCO International. Dave Schulz, Senior Vice President and Chief Financial Officer Raymond James 39 th Annual Investors Conference, March 7, 2018
WESCO International Dave Schulz, Senior Vice President and Chief Financial Officer 2 Safe Harbor Statement All statements made herein that are not historical facts should be considered as forward-looking
More informationSupplemental Financial Schedules May 19, 2015
Supplemental Financial Schedules May 19, 2015 The presentations and related schedules contain financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP).
More informationSecurities Analyst Meeting 2017 PRINTING. Enrique Lores President, Imaging and Printing Business
Securities Analyst Meeting 2017 PRINTING Enrique Lores President, Imaging and Printing Business Forward-looking statements Today s presentations contain forward-looking statements that involve risks, uncertainties
More informationBASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses. October 13, 2017
BASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses October 13, 2017 Cautionary note regarding forward-looking statements This presentation contains
More informationFinancial Objectives. Forward Looking Statements. Symantec 2012 Financial Analyst Day 5/24/2012. James Beer. EVP & Chief Financial Officer
Financial Objectives James Beer EVP & Chief Financial Officer 1 Forward Looking Statements This presentation contains statements regarding our projected financial and business results, which may be considered
More informationPfizer To Acquire Hospira
For immediate release: February 5, 2015 Media Contact: Joan Campion (212) 733-2798 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer To Acquire Hospira - Transaction will significantly enhance Pfizer
More informationTrex Company Investor Presentation. May 2017
Trex Company Investor Presentation May 2017 1 Safe Harbor / Non-GAAP Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationFresenius Investor News
health care worldwide October 31, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationStericycle, Inc. Q NASDAQ: SRCL
Stericycle, Inc. Q1 2015 NASDAQ: SRCL Forward - Looking Statements This presentation may contain forward-looking statements that involve a number of risks and uncertainties and our actual results could
More informationFresenius Investor News
health care worldwide August 3, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More information2017 Annual Meeting of Shareholders
2017 Annual Meeting of Shareholders May 17, 2017 The world leader in serving science Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following presentations about the company s
More informationFresenius Investor News
Analysts Meeting and Live video webcast today Fresenius Medical Care at 2.30 p.m. CET / 8.30 a.m. EDT Fresenius AG at 4.30 p.m. CET / 10.30 a.m. EDT health care worldwide May 4, 2005 Contact: Birgit Grund
More informationLuc Gregoire Chief Financial Officer. Drexel Hamilton Annual Telecom, Media and Technology Conference September 6, 2017
Luc Gregoire Chief Financial Officer Drexel Hamilton Annual Telecom, Media and Technology Conference September 6, 2017 Forward Looking Statements This presentation and oral statements made from time to
More informationIBM 4Q 2016 Earnings. January 19, ibm.com/investor
IBM 4Q 2016 Earnings January 19, 2017 ibm.com/investor Forward Looking Statements and Non-GAAP Information 2 Certain comments made in this presentation may be characterized as forward looking under the
More informationTriNet Group, Inc. William Blair Growth Company Conference June 2017
TriNet Group, Inc. William Blair Growth Company Conference June 2017 Disclaimer Cautionary Note Regarding Forward-Looking Statements and Other Financial Information This presentation contains statements
More informationCalix Q Financial Results. February 13, 2018
Calix Q4 2017 Financial Results February 13, 2018 Safe Harbor This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
More informationConference Call FY/17 Results
Conference Call FY/17 Results Bad Homburg, 27 February 2018 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking
More informationMorgan Stanley Conference. November 15, 2017
Morgan Stanley Conference November 15, 2017 1 Forward Looking Statements Certain statements in this release or presentation, other than purely historical information, including estimates, projections,
More informationWILLIAM BLAIR GROWTH STOCK CONFERENCE. June 14, 2017
WILLIAM BLAIR GROWTH STOCK CONFERENCE June 14, 2017 Safe Harbor Statement Statements made in this presentation which are not statements of historical fact are forward-looking statements and are subject
More informationIBM Business Perspective 2006
IBM Business Perspective 2006 Patricia Murphy Vice President, Investor Relations IBM Corporation Certain comments made in the presentation may be characterized as forward looking under the Private Securities
More informationGood afternoon, welcome to our annual shareholder meeting. I am Lee Rudow, President and CEO of Transcat and I will provide an overview of the
1 Good afternoon, welcome to our annual shareholder meeting. I am Lee Rudow, President and CEO of Transcat and I will provide an overview of the current state of Transcat an our direction for FY17 and
More informationARRIS Announces Acquisition of BigBand Networks. Building Leadership in Video Networking October 11, 2011
ARRIS Announces Acquisition of BigBand Networks Building Leadership in Video Networking Safe Harbor This presentation contains forward looking statements. These statements include, among others, accelerating
More informationBemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference
Bemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference September 14, 2011 Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the
More informationOur unique, sustainable attributes
Investor overview At Texas Instruments, our focus is on building a better future as we design, make and sell semiconductors. We have about 100,000 customers all over the world who use our chips. For more
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationProposal to Acquire Andrew Corporation
Proposal to Acquire Andrew Corporation Creating The Global Leader in Providing Last Mile Solutions for Communications Networks Frank Drendel Chairman and Chief Executive Officer Brian Garrett President
More informationInvestor Presentation. May 2013
Investor Presentation May 2013 MAHINDRA. A HISTORY OF RISING. We will challenge conventional thinking and innovatively use all our resources to drive positive change in the lives of our stakeholders and
More informationAvery Dennison Investor Presentation August 2014
Avery Dennison Investor Presentation August 2014 Unless otherwise indicated, the discussion of the company s results is focused on its continuing operations, and comparisons are to the same period in the
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationRecommended acquisition of The BSS Group plc. 5 July 2010
Recommended acquisition of The BSS Group plc 5 July 2010 Important information This document is being made available only to persons who fall within the exemptions contained in Article 19 and Article 49
More informationPurchase Of Craftsman Brand. January 5, 2017
Purchase Of Craftsman Brand January 5, 2017 Cautionary Statements Stanley Black & Decker makes forward-looking statements in this presentation which represent its expectations or beliefs about future events
More informationBusiness Outcome Led, Technology Enabled
Business Outcome Led, Technology Enabled Safe-Harbor Statement Statements in this presentation and remarks and responses made in connection with this presentation include forward-looking statements that
More informationOppenheimer 16 th Annual Consumer Conference
Oppenheimer 16 th Annual Consumer Conference Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
More informationCautionary Note Regarding Forward Looking Statements
If(we) Acquisition Cautionary Note Regarding Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationFresenius Investor News
health care worldwide February 22, 2007 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationKeysight Technologies Investor Presentation. December 2017
Keysight Technologies Investor Presentation December 2017 Page 1 Safe Harbor This communication contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the
More informationRockwell Automation Company Overview January 2017
Rockwell Automation Company Overview January 2017 2 Safe Harbor Statement This presentation includes statements related to the expected future results of the company and are therefore forward-looking statements.
More informationFINANCIAL PERSPECTIVES
FINANCIAL PERSPECTIVES M³ - Meet Merck Management Marcus Kuhnert, CFO Darmstadt December 10, 2015 Disclaimer Cautionary Note Regarding Forward-Looking Statements This communication may include forward-looking
More informationSales and net income reach all-time highs 6% dividend increase proposed Positive Group outlook for 2015
Investor News February 25, 205 Birgit Grund Senior Vice President Investor Relations Fresenius SE & Co. KGaA Else-Kröner-Straße 6352 Bad Homburg Germany T +49 672 608-2485 F +49 672 608-2488 birgit.grund@fresenius.com
More information2016 half year results August 10 th 2016
2016 half year results August 10 th 2016 HALF YEAR RESULTS 2016 1 Certain statements in this document are forward looking statements. These forward looking statements speak only as at the date of this
More informationChristine Skold. Vice President, Investor Relations and Corporate Communications
Christine Skold Vice President, Investor Relations and Corporate Communications 2 Safe Harbor Statement The Company claims the protection of the safe-harbor for forward-looking statements contained in
More informationGATX Corporation Investor Relations - Press Release
Investor Relations Corporate Information Stock Information Press Releases Corporate Governance SEC Filings Financial Information Fixed Income Frequently Asked Questions Home > Investor Relations > Press
More informationAmdocs Limited Reports Revenue Growth of 19.4% in Third Quarter
Amdocs Limited Reports Revenue Growth of 19.4% in Third Quarter Key highlights: Revenue of $450.2 million, in line with guidance Sequential revenue growth of 1.7% Proforma EPS increases 30.4% to $0.30,
More informationAgilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks
Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2017. With me
More informationBrightcove Inc. Investor Presentation. May 2017
Brightcove Inc. Investor Presentation May 2017 Safe Harbor Statement These slides and the accompanying oral presentation contain certain forward-looking statements" within the meaning of the Private Securities
More informationMay 5, ABB acquires Ventyx. ABB Group. May 5, 2010
ABB acquires Ventyx Safe-harbor statement This presentation includes forward-looking information and statement s including statements concerning the outlook for our businesses. These statements are based
More informationLas Vegas Sands Corp. Reports Landmark Fourth Quarter and Full Year 2011 Results
Las Vegas Sands Corp. Reports Landmark Fourth Quarter and Full Year 2011 Results Declares Annual Dividend of $1.00 per Share; Fourth Quarter Net Revenue Increases 26.3% to Record $2.54 Billion; Fourth
More informationFor personal use only
ASX Market Disclosure Aconex Agrees to Acquire Conject and Launches Capital Raising Acquisition Will Provide Strong Construction Collaboration Market Footprint throughout Europe MELBOURNE, Australia, 17
More informationMonotype. Investor Update September 2017
Monotype Investor Update September 2017 1 Safe Harbor This presentation contains forward-looking statements, including those related to our investment thesis, including scale and expansion, the growth
More informationInventergy Global, Inc. (NASDAQ: INVT), Target Price: $10.30)
Equity Telecom / Telecom Services Update (December 11, 2015) Inventergy Global, Inc. (NASDAQ: INVT), Target Price: $10.30) Based in Campbell, CA, Inventergy (NASDAQ: INVT, Inventergy ) is an intellectual
More informationAristocrat Leisure Limited Acquisition of Plarium Global Limited. 10 August 2017
Aristocrat Leisure Limited Acquisition of Plarium Global Limited 10 August 2017 Disclaimer This document and any oral presentation accompanying it has been prepared in good faith, however, no express or
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationAnalyst Conference Call Q1/13 Results. April 30, 2013
Analyst Conference Call Q1/13 Results April 30, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could
More information2014 First Quarter Business Review
2014 First Quarter Business Review (unaudited) April 24, 2014 2014 First Quarter Business Review Forward Looking Statements This presentation contains forward-looking information about 3M's financial results
More informationBruker drives profitable growth by enabling breakthrough discoveries & development of new applications that improve the quality of human life
Bruker drives profitable growth by enabling breakthrough discoveries & development of new applications that improve the quality of human life Innovation with Integrity BRUKER CORPORATION Safe Harbor Statement
More informationLogitech Q1 Fiscal Year 2015 Preliminary Financial Results Management s Prepared Remarks (July 23, 2014)
Logitech is posting a copy of these prepared remarks, its press release and accompanying slides to its investor website. These prepared remarks will not be read on the call. We refer both to GAAP and to
More informationLetter to Shareholders Q2 FY18
November 2, 2017 Letter to Shareholders Q2 FY18 CIRRUS LOGIC, INC. 800 WEST SIXTH STREET, AUSTIN, TEXAS 78701 November 2, 2017 Dear Shareholders, Cirrus Logic reported outstanding results in the September
More informationSustained impetus across verticals drives Biocon s Q1 growth
Bangalore, India July 25, 2012 Sustained impetus across verticals drives Biocon s Q1 growth Revenues at ` 593 Crores; EBITDA at ` 139 Crores; PAT at ` 79 Crores Commenting on the results, Chairman and
More informationWillis Group and Towers Watson Announce Merger to Create Leading Global Advisory, Broking and Solutions Firm
News Release Willis Group and Towers Watson Announce Merger to Create Leading Global Advisory, Broking and Solutions Firm Combination offers clients a broader range of advice, analytics, specialty capabilities
More informationAcquisition of Amplify Snack Brands, Inc. December 18, 2017
Acquisition of Amplify Snack Brands, Inc. December 18, 2017 1 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. Many of these forward-looking statements can be identified
More informationUnilever Investor Event 2017 Graeme Pitkethly 29 th November 2017
Unilever Investor Event 2017 Graeme Pitkethly 29 th November 2017 What you have heard so far Driving growth in each Category Fuelling growth and margin expansion Personal Care Home Care Foods & Refreshment
More informationOPENING & WELCOME TOM MCCALLUM. Vice president, Investor Relations
OPENING & WELCOME TOM MCCALLUM Vice president, Investor Relations MORNING SESSION 10:30 11:00 a.m. Jim Whitehurst, president and chief executive officer 11:00 11:45 a.m. Frank Calderoni, executive vice
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationWuXi PharmaTech: Building an Open-Access Capability and Technology Platform. Jefferies Healthcare Conference November 2014
WuXi PharmaTech: Building an Open-Access Capability and Technology Platform Jefferies Healthcare Conference November 2014 Cautionary Note Regarding Forward-Looking Statements This presentation contains
More informationPayPal Reports First Quarter 2017 Results and Raises Financial Guidance for Full Year
PayPal Reports First Quarter 2017 Results and Raises Financial Guidance for Full Year Q1 GAAP EPS increased 6% to $0.32, non GAAP EPS increased 19% to $0.44 $5 billion stock repurchase authorization announced
More informationCOMPANY OVERVIEW JOHN MORIKIS CHAIRMAN, PRESIDENT & CHIEF EXECUTIVE OFFICER FINANCIAL COMMUNITY PRESENTATION OCTOBER 3, 2017
COMPANY OVERVIEW JOHN MORIKIS CHAIRMAN, PRESIDENT & CHIEF EXECUTIVE OFFICER Forward Looking Statement The presentations today will contain certain forward looking statements," as defined under U.S. federal
More informationFinancial and other information related to the intended combination of Intrum Justitia and Lindorff published by Intrum Justitia
Stockholm 12 June 08:10 CET (page 1 of 5) PRESS RELEASE Intrum Justitia AB (publ) Corporate identity no.:556607-7581 Financial and other information related to the intended combination of Intrum Justitia
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationCSC Separating Into Two Industry Leading Public Companies. May 19, 2015
CSC Separating Into Two Industry Leading Public Companies May 19, 2015 Forward looking statements All written or oral statements made by CSC at this meeting or in these presentation materials that do not
More informationUBS Global Life Sciences Conference
September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &
More informationTractor Supply Company. Third Quarter 2015
Tractor Supply Company Third Quarter 2015 Safe Harbor Statement The Company claims the protection of the safe-harbor for forward-looking statements contained in the Private Securities Litigation Reform
More informationUSA Compression Partners, LP Acquisition of CDM Resource Management LLC January 16, 2018
USA Compression Partners, LP Acquisition of CDM Resource Management LLC January 16, 2018 Disclaimer This presentation contains forward-looking statements relating to the operations of USA Compression Partners,
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationBerendsen plc. Timetable
Timetable 14:00 14:10 Trading Update & Q&A 14:10 15:20 Group Strategy Update & Q&A 15:20 15:30 Break 15:30 17:20 Breakout session by Business Line Workwear Facility Cleanroom Mats Washroom Hospitality
More informationStrategy Agricultural Products
Strategy Agricultural Products Hans W. Reiners President Agricultural Products Division August 2005 1 Agricultural Products Strategy Delivers Results 2 Half-Year 2005 Performance 3 Setting the Benchmark
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationAmpco-Pittsburgh Corporation. November 17, 2016 Southwest IDEAS Investor Conference
Ampco-Pittsburgh Corporation November 17, 2016 Southwest IDEAS Investor Conference 2 The Private Securities Litigation Reform Act of 1995 (the Act ) provides a safe harbor for forwardlooking statements
More informationCompany Overview. November 2017
Company Overview November 2017 DCC Overview DCC is a leading international sales, marketing and support services group operating across four divisions Profit by division * Profit by geography * 12% 5%
More informationThird quarter and first nine months 2017 Results Release. October 19 th, 2017
Third quarter and first nine months 2017 Results Release October 19 th, 2017 Safe harbor statement Any statements contained in this document that are not historical facts are forward-looking statements
More informationEMEA MARKET MARKETING HEIDI ARKINSTALL CMO. RENE OEHLERKING Jaybird. UJESH DESAI GM, Gaming
EMEA MARKET MARKETING HEIDI ARKINSTALL CMO RENE OEHLERKING Jaybird UJESH DESAI GM, Gaming FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of the U.S.
More informationDefinitive Merger Agreement Conference Call
Definitive Merger Agreement Conference Call Committed to providing products and services that ensure the best possible patient outcomes August 15, 2017 NASDAQ: SKLN Forward-Looking Statements This presentation
More informationLeading the way towards a Smart Grid Capital Market Day London, December 5, 2013
Jan Mrosik CEO Smart Grid Division Leading the way towards a Smart Grid Capital Market Day London, Safe Harbour Statement This document contains statements related to our future business and financial
More informationLA-Z-BOY INCORPORATED
LA-Z-BOY INCORPORATED November 2017 Providing comfort to America for 90 years FORWARD-LOOKING DISCLAIMER This presentation contains forward-looking statements that involve uncertainties and risks as detailed
More informationSoftware AG Heading for Growth
Software AG Heading for Growth Karl-Heinz Streibich, CEO June 01, 2006 Credit Suisse European Technology Conference, Barcelona, Spain This presentation contains forward-looking statements based on beliefs
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More information